Taysha Gene Therapies Inc

TSHA

Company Profile

  • Business description

    Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

  • Contact

    3000 Pegasus Park Drive
    Suite 1430
    DallasTX75247
    USA

    T: +1 214 612-0000

    https://www.tayshagtx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    99

Stocks News & Analysis

stocks

Big-four bank earnings surge but revenue growth elusive

Shares sell off after results.
stocks

This ASX supermarkets business is now underperforming its largest competitor

Competition restrains long-term margins.
stocks

Apple earnings: Let the iPhone 17 cycle rip

We raise our fair value estimate for Apple stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,923.8030.30-0.34%
CAC 407,976.12138.72-1.71%
DAX 4023,991.27301.11-1.24%
Dow JONES (US)49,012.36486.91-0.98%
FTSE 10010,363.9314.89-0.14%
HKSE26,095.88319.351.24%
NASDAQ24,992.77121.68-0.48%
Nikkei 22559,513.12228.200.38%
NZX 50 Index13,097.6858.480.45%
S&P 5007,191.6038.52-0.53%
S&P/ASX 2008,697.1028.50-0.33%
SSE Composite Index4,112.164.650.11%

Market Movers